| Pfizer and BioNTech announced Friday that they are modifying their clinical trial to include a third shot at least two months after the initial two-dose regimen for children under age 5. The companies reported that two doses of the pediatric vaccine failed in 2-, 3- and 4-year-olds to trigger an immune response comparable to what was generated in teens and older adults. | 
No comments:
Post a Comment